Objective-Low and nontoxic proteasome inhibition has anti-inflammatory, antiproliferative, and antioxidative effects on vascular cells in vitro and in vivo. We hypothesized that low-dose inhibition of the proteasome could provide antiatherogenic protection. The present study investigated the effect of low-dose proteasome inhibition on early lesion formation in low-density lipoprotein receptor-deficient mice fed a Western-type diet. Methods and Results-Male low-density lipoprotein receptor-deficient mice, 10 weeks old, were fed a Western-type diet for 6 weeks with intraperitoneal injections of bortezomib or solvent. Bortezomib was injected at a dose of 50 mg/kg body weight. Cholesterol plasma levels were not affected by bortezomib treatment. En face Oil Red O staining of aortae and aortic root cryosections demonstrated significant reduction of atherosclerotic lesion coverage in bortezomib-treated animals. Bortezomib significantly reduced vascular cellular adhesion molecule-1 expression and macrophage infiltration as shown by histological analysis. Bortezomib treatment resulted in a significant reduction of superoxide content, lipid peroxidation and protein oxidation products, serum levels of monocyte chemoattractant protein-1, and interleukin-6. Gene expression microarray analysis showed that expressional changes induced by Western-type diet were attenuated by treatment with low-dose bortezomib.
A therosclerosis is a vascular disease associated with chronic inflammation and oxidative stress. The pathophysiological process of plaque formation involves early endothelial dysfunction due to increased levels of endogenous reactive oxygen species. As a consequence, the bioavailability of NO and endothelium-dependent vasodilation are reduced. Those alterations promote increased expression of adhesion molecules (eg, vascular cellular adhesion molecule-1 [VCAM-1]) in endothelial cells followed by cell surface adhesion of circulating leukocytes and their subsequent migration into the vessel wall. Accumulating mononuclear cells release a variety of cytokines and chemokines, such as monocyte chemoattractant protein-1 (MCP-1), guiding more inflammatory cells to the site and thereby driving the progression of the atherosclerotic lesion. Ultimately, smooth muscle cells, immune cells, and cholesterol-loaded macrophages accumulate and contribute to the deposition of extracellular matrix, lipids, and necrotic debris within the developing atherosclerotic plaque which in turn results in narrowing of the vessel diameter. 1, 2 The ubiquitin-proteasome system (UPS) is the major pathway for intracellular protein degradation in eukaryotic cells. 3 Beyond its function to degrade dysfunctional proteins, the UPS is involved in various regulatory processes including transcription, apoptosis, and cell cycle. For example, the UPS activates important transcription factors, such as proinflammatory nuclear factor-kB and the oxidative stress-related nuclear erythroid 2-related factor 2. 4 An excellent review of studies concerning the UPS in atherosclerosis by Herrmann et al 5 showed the progress made in recent years toward understanding the role of UPS in plaque formation. A dual role of the UPS was postulated: First, the UPS contributes to lesion formation by mediating the inflammatory response; second, it may have a protective role by eliminating dysfunctional proteins. Accordingly, differential effects of proteasome inhibition (PI) were suggested, depending on the stage of atherosclerotic disease. 5 Cellular responses to PI are divergent and range from induction of apoptosis to protection from cell death. 6 Cytotoxic properties of PI were recognized early and led to the clinical application of the proteasome inhibitor bortezomib in treatment of multiple myeloma. 7 Furthermore, proteasome inhibitors have also been identified as potent anti-inflammatory drugs in several acute and chronic inflammatory animal models. 6 We proposed the concept of proteasome inhibitors acting as poisons or remedies. That is, seemingly contradictory effects of PI may be the result of different dosages used, or could depend on a cell-or tissue-specific susceptibility to inhibitors. 6 Depending on the resulting degree of inhibition, PI could thus mediate either cytotoxic or beneficial effects.
Treatment with low doses of proteasome inhibitors exerted favorable anti-inflammatory and antioxidative effects in vascular cells. [8] [9] [10] [11] [12] Moreover, low-dose PI was shown to enhance endothelial nitric oxide synthase expression and activity, improved endothelial function, 13 and prevented tumor necrosis factor--induced vascular dysfunction by reducing superoxide production and decreasing endothelin-1 levels in rat aortic rings. 14 We have recently shown that low-dose PI downregulates tumor necrosis factor--induced expression of VCAM-1 in endothelial cells and in a hypertensive rat model, which suggests that low-dose PI suppresses inflammatory cell adhesion in atherogenesis. 11 Taken together, low-dose PI effectively modulates factors and processes particularly important during early-stage atherosclerosis.
On the basis of these considerations, we hypothesized that low-dose PI provides antiatherogenic protection and could delay the onset of atherosclerosis. We investigated early lesion formation in Western-type diet-fed low-density lipoprotein receptor-deficient (LDLR−/−) mice that represent a well-established model of hypercholesterolemia-induced atherosclerosis. Animals were treated with low doses of the boronate-type proteasome inhibitor bortezomib. The observed attenuation of atherosclerotic lesion formation supports our hypothesis that low-dose PI provides antiatherogenic protection in vivo.
Methods

Materials
Unless otherwise specified, all reagents and media were purchased from Sigma Chemicals, Germany. Bortezomib was kindly provided by Millenium Pharmaceuticals.
Animal experiments
Animal experiments were approved by the local authority (Landesamt für Gesundheit und Soziales, Berlin) and were performed according to institutional guidelines. Dosing studies were performed using Ub G76 Vgreen fluorescence protein (GFP)-1 mice (Charles River, Germany), which express the GFP as transgene from a chicken -actin promoter. 15 Ub G76 V -GFP-1 males were bred with C57BL/6 females for maintenance. Heterozygous Ub G76V -GFP1 adult males were injected once with the indicated doses of bortezomib or saline, 24 hours before they were euthanized by collection of whole blood (by puncture of the retroorbital vein plexus) under isoflurane anesthesia. After perfusion with PBS, heart and aortae were snap-frozen in liquid nitrogen for storage at −80°C.
Male 10-week-old LDLR−/− mice (B6.129S7-Ldlr tm1Her /J; JAX Mice, Boston) were divided into 3 body weight and serum cholesterol-matched groups. Mice of the Western diet (WD) group were fed a high-fat diet for 6 weeks ad libitum ( Western-type diet containing 21% butterfat, 17% casein, 0.21% cholesterol; Ssniff, Soest, Germany) and received intraperitoneal saline injections. Mice of the WD1Bor group received the same Western-type diet for 6 weeks and intraperitoneal injections of bortezomib (50 mg/ kg body weight [BW]) twice weekly. The control diet (CD) group received a low-fat control diet. General condition and body weight were monitored.
Mice were fasted for 2 hours, anesthetized in an isoflurane-loaded box, and euthanized. After perfusion with PBS, heart and aortae were dissected under a stereomicroscope (Leica), snap-frozen in liquid nitrogen, and stored at −80°C or fixed in formalin. Livers were snap-frozen immediately for analysis of proteasomal activity.
Measurement of Proteasomal Activity
Measurement of proteasomal activity in liver lysates was performed as described previously 11 (see online-only Data Supplement).
staining and Analysis of Atherosclerotic lesions
For en face aortic lesion analysis, thoracic aortae were stained with Oil Red O. Lesion area in the aortic arch was calculated as the percentage of total aortic arch area. Cryosections of aortic roots were stained with Oil Red O and counterstained with hemalaun. Analysis was performed under standardized conditions using Zeiss Axiovision Software. Results were calculated as the percentage of lipid-stained area of total vessel area (for details of staining, imaging, and quantification refer to the online-only Data Supplement).
immunohistochemistry
Immunohistochemistry of acetone-fixed 5-mm aortic root cryosections was performed using anti-VCAM-1 (Pharmingen) and anti-Mac-2 (Cedarlane laboratories). Following hemalaun counterstain sections were digitally photographed under standardized conditions using Zeiss AxioCam MrC and analyzed using Zeiss AxioVision software (for details of staining protocols refer to the online-only Data Supplement).
in situ superoxide detection
Dihydroethidium staining was used to assess vascular superoxide production (see online-only Data Supplement).
Measurement of serum lipids and lipid Peroxidation Products
Plasma total cholesterol and triglyceride concentrations were measured by colorimetric enzymatic assay ( CHOL-PAP and TG GPO-PAP; Roche-Diagnostics, Mannheim, Germany). High-density lipoprotein-cholesterol concentration was separated by the phosphotungstate-magnesium precipitation technique, followed by measurement as for total cholesterol.
Lipid hydroperoxides were determined in mouse serum by measurement of the formation of thiobarbituric acid reactive substances, as described previously 11, 16 (see online-only Data Supplement).
serum levels of McP-1 and il-6
Serum levels of mouse soluble MCP-1 and mouse interleukin-6 (IL-6) were measured by Mouse CCL2/JE/MCP-1 or IL-6 Quantikine ELISA Kit (R&D Systems, Inc., Minneapolis, MN) according to the manufacturer's protocol.
Western Blot
Tissue lysis and Western blot analysis were performed according to the established protocols 11 (see online-only Data Supplement).
Quantitative real-Time rT-Pcr
RNA isolation and real-time reverse transcription polymerase chain reaction were performed as previously described 11 (see online-only Data Supplement). June 2012
Gene expression Microarray and Bioinformatical Analysis
Agilent Whole Mouse Genome Oligo Microarrays of pooled aortic lysates were performed and analyzed as described in detail in the online-only supplement. In brief, RNA was isolated using TRIzol reagent, quality-checked via the Agilent 2100 Bioanalyzer platform and amplified. RNA expression was analyzed in 2 independent experiments. For each experiment, RNA from 4 animals per group (CD, WD, WD+Bor) was pooled. Cy3-labeled fragmented cRNA (1.65 mg) in hybridization buffer was hybridized overnight (17 hours, 65°C) to Agilent Whole MouseGenome Oligo Microarrays (444K). Fluorescence signals of the hybridized Agilent Microarrays were detected using Agilent's Microarray Scanner System (Agilent Technologies, Palo Alto, CA). The Agilent Feature Extraction Software was used to read out and process the microarray image files.
For determination of differential gene expression, Feature Extraction Software-derived output data files were further analyzed using the Rosetta Resolver gene expression data analysis system (Rosetta Biosoftware, Seattle, WA). To receive unbiased information on the functional pattern among genes regulated by Western-type diet, the software tool Ontologizer v2.1 (Computational Biology Group, Institute for Medical Genetics and Human Genetics, Charité-Universitaetsmedizin Berlin, Germany, http://compbio.charite.de/index.php/ontologizer2. html) was used to analyze the microarray data.
Analysis of Vasoreactivity
Analysis of vasoreactivity of mouse aortic rings was performed according to established protocols 8, 13, 14 (see online-only Data Supplement).
statistical Analysis
Data are presented as meanSEM. Comparisons between groups were made using Mann-Whitney or Student t test, or 1-way ANOVA plus Tukey post hoc test (SPSS v18.0) as appropriate. P0.05 was considered significant.
Gene expression microarray data were analyzed using the Rosetta Resolver gene expression data analysis system. A P value was calculated for every fold change using the Rosetta Resolver error model. All genes with expression ratios 0.5 and 2 and a P0.01 were selected to generate the tables of significantly regulated genes.
results dose Adjustment for Nontoxic Pi
To define a low and nontoxic, but effective dose of the proteasome inhibitor bortezomib, we performed experiments with Ub G76 V -GFP-1 reporter mice. After administration of 500 mg/ kg BW bortezomib, we observed an accumulation of Ub G76-V -GFP in cell lysates of aortae as well as in heart tissue as measured in Western blots, upon probing with anti-GFP antibodies (Figure 1 ). Western blot analyses of the same cell lysates with antiubiquitin antibodies revealed that 50 mg/kg bortezomib was sufficient to cause an increase in the level of ubiquitin conjugates, albeit less pronounced than in lysates of animals treated with 500 mg/kg BW bortezomib ( Figure 1 ). Application of 25 mg/kg BW bortezomib had no measurable effects. Therefore, 50 mg/kg BW bortezomib, which is well below the toxic dosage of 100 mg/kg BW established for monkeys and rodents, 7,17 represents a moderate but effective dose for PI in the cardiovascular system and was used in the current study.
Male LDLR−/− mice, 10 weeks of age, were fed a Western-type diet for 6 weeks and received either intraperitoneal bortezomib injections (WD+Bor; n512) or saline injections (WD; n512) twice weekly for 6 weeks. Mice kept on a normal low-fat control diet served as control group (CD; n56). Bortezomib treatment (WD1Bor) resulted in a 32.8% inhibition of the chymotrypsin-like activity compared with WD animals, as measured in liver lysates 24 hours after the final injection (Table) and was well tolerated by the mice. Body weight was similar in all groups at time of harvesting. No abnormalities in livers, kidneys, or blood counts were detected after bortezomib treatment (data not shown). No signs of Figure I in the online-only Data Supplement). WD caused significant elevation of plasma cholesterol and triglyceride concentrations. Bortezomib treatment had no effect on plasma cholesterol or triglyceride levels (Table) .
low-dose Bortezomib Attenuates early Atherosclerotic lesion Formation
LDLR−/− mice fed a Western-type diet for 6 weeks developed early lesions almost exclusively in the aortic arch area and the aortic root, whereas aortas of age-matched CD LDLR−/− had no detectable lesions, as shown by en face and cross-sectional analysis. En face analysis of atherosclerotic lesions in the aortic arch (Figure 2A ) revealed a significant reduction of lesion area in the WD1Bor compared with the WD group (0.520.08 versus 1.290.20% of total aortic area; P50.007). Similarly, Oil Red O-stained area in the aortic root ( Figure 2B ) was significantly reduced in WD1Bor animals compared with WD mice (5.670.59 versus 19.362.46% of total vessel area; P0.001).
low-dose Bortezomib Provides Anti-inflammatory Protection in ldlr−/− Mice
VCAM-1 expression was examined in aortic root cryosections of LDLR−/− mice. Bortezomib treatment significantly decreased VCAM-1 staining (2.850.42% versus 6.551.15%; P50.038; Figure 2C ). Compared with CD mice, serum levels of MCP-1 were significantly increased in WD mice. Bortezomib significantly lowered MCP-1 serum levels of WD mice (39.723.07 versus 53.492.85 pg/mL; P50.004; Figure 3A ). Mac-2-positive macrophage content in aortic root cryosections was decreased in WD1Bor compared with WD animals (2.610.25% versus 9.101.41%; P0.001; Figure 2D ). Serum levels of IL-6 were found to be strongly increased in WD compared with CD mice. Remarkably, in WD1Bor mice, IL-6 levels were maintained nearly at the level of CD mice ( Figure 3B ).
low-dose Bortezomib exerts Antioxidative effects in ldlr−/− Mice
We performed in situ detection of superoxide production by fluorescence microscopy in sections of the ascending aorta. Dihydroethidium fluorescence revealed marked reduction of superoxide release in WD1Bor compared with WD mice (196.9936.97 versus 368.2646.52 arbitrary units; P50.02; Figure 2E ). Serum levels of lipid peroxidation products measured as thiobarbituric acid reactive substances were significantly decreased (4.370.24 versus 7.580.53 mmol/L; P0.001; Figure 4A ) in WD1Bor mice compared with WD mice. Stable vascular oxidation products were examined in aortic lysates. Bortezomib treatment caused reduction of protein oxidation as measured by detection of carbonyl groups using OxyBlot compared with WD and even with CD animals ( Figure 4B ).
We previously described transcriptional downregulation of nicotinamide adenine dinucleotide phosphate oxidase subunit Nox4 expression by low-dose PI in endothelial cells. 8 In line with this finding, real-time reverse transcription polymerase chain reaction using aortic RNA showed a reduction of Nox4 mRNA expression in WD1Bor mice compared with WD mice ( Figure 4C ).
low-dose Bortezomib Attenuates Wd-induced changes in Gene expression
Expression microarray analysis identified 3900 genes that were regulated by more than 2-fold in WD mice compared with CD animals. Interestingly, only 1500 of these genes were regulated by more than 2-fold in mice that received bortezomib in addition to Western-type diet.
Bioinformatic analysis revealed that genes associated with the gene ontology terms cell communication (gene ontology: 0007154), oxidation reduction (gene ontology:0055114), and generation of precursor metabolites and energy (gene ontology:0006091) were significantly overrepresented (P0.001) among regulated genes in Western-type diet mice ( Figure II in the online-only Data Supplement). Only less than half of this subset of genes was regulated by more than 2-fold in mice that received bortezomib in addition to Western-type diet.
Similar results were obtained when we focused on a selection of genes which have been shown to play a role in atherosclerosis ( Figure 5 ). Here, bortezomib again markedly suppressed gene expression changes induced by Western-type diet, including MCP-1, VCAM-1, and IL-6, confirming our above-described observations.
Taken together, WD-induced regulation of genes was attenuated by bortezomib treatment, leading to an expressional pattern in WD1Bor animals approaching that of CD animals. Surprisingly, no significant change in the expression of catalytic and noncatalytic proteasomal subunits was detected in all groups. Ubiquitin C-terminal hydroxylase L1 (Uchl1), a deubiquitinating hydrolase that has been associated with the suppression of neointima formation and suppression of nuclear factor-kB activation, 18 shows a favorable regulation in WD1Bor compared with WD mice.
Vasoreactivity of Aortic rings is Preserved
Determination of vasoreactivity is of particular interest, because data concerning the effect of PI on vasoreactivity are controversial. 19 To assess possible modulation of vasoreactivity by bortezomib treatment, we evaluated endothelium-dependent and endothelium-independent vasodilation of isolated aortic rings by acetylcholine and sodium nitroprusside, respectively. As shown in Figure IIIA in the online-only Data Supplement, vasoreactivity in response to acetylcholine was equally potent in the WD and WD1Bor groups. Similarly, endothelium-independent vasodilation after sodium nitroprusside application was similar in both groups ( Figure IIIB in the online-only Data Supplement). Aortic rings tested did not show atherosclerotic lesions as shown for the aortic arch, which is consistent with the early-stage atherosclerosis in the current study.
discussion
In the present study we have shown an antiatherosclerotic effect of low-dose treatment with the proteasome inhibitor bortezomib in LDLR−/− mice. Early atherosclerotic lesion formation was significantly attenuated by bortezomib treatment, without changing plasma cholesterol levels. This was attributed to a marked reduction of oxidative stress and vascular inflammation.
An important issue was the adjustment of PI dosage such that detectable modulation of proteasome activity could be achieved without inducing toxicity, even during long-term treatment. Because no such studies have been conducted in mice regarding the cardiovascular system in this context, we made use of the Ub G76 V -GFP-1 transgenic reporter mouse. 15 Degradation of the Ub G76 V -GFP fusion protein is readily detectable and is sensitive to PI. 20 A level of 500 mg/kg BW bortezomib was highly effective for PI in this system; however, this dose is toxic. 7 A considerably lower nontoxic dose (50 mg/kg BW) still led to detectable accumulation of polyubiquitinated proteins, thereby demonstrating at least partial inhibition of proteasomal activity. This was further verified by observation of a reduced chymotrypsin-like proteasome activity in liver tissue after 6-week treatment of mice with this low dose of bortezomib. Bortezomib treatment at this dosage for 6 weeks did not lead to apoptosis in the vasculature. According to a previous report on hypertensive rats, 11 partial PI at this dosage is also not toxic, while exerting potent antioxidative and anti-inflammatory effects. Antiatherogenic effects of low-dose bortezomib treatment can therefore be attributed to partial inhibition of the proteasome.
There is substantial evidence from cell culture experiments supporting anti-inflammatory and antioxidative properties of low-dose PI. [8] [9] [10] [11] [12] 21 One mechanism mediating the antioxidative effects of low-dose PI in cardiovascular cells is stabilization of oxidative stress-related transcription factor nuclear erythroid 2-related factor 2. 9, 21 In line with these previous in vitro observations, we found definite antioxidative effects of low-dose bortezomib treatment in hypercholesterolemic LDLR−/− mice in the present study. Serum content of lipid peroxidation products, which was markedly increased in hypercholesterolemic LDLR−/2 mice compared with control diet-fed LDLR−/− mice, was significantly decreased by bortezomib treatment. Similar data were obtained on stable protein oxidation and lipid peroxidation products. Moreover, vascular superoxide production, measured by dihydroethidium fluorescence, was decreased by bortezomib, which is similar to results previously observed in hypertensive rats treated with bortezomib. 11 Nicotinamide adenine dinucleotide phosphate oxidases are considered a major source of reactive oxygen species in the vasculature. 22 Gene expression microarray analysis revealed that of all Nox isoforms, only Nox4 was significantly regulated in our model, which was confirmed by real-time reverse transcription polymerase chain reaction. This is of particular interest, because previous cell culture experiments identified Nox4 as susceptible to PI. 8 The underlying mechanism for Nox4 downregulation by low-dose PI is unknown. Above all, gene expression microarray analysis indicates that certainly multiple proteins contribute to the antioxidative effect of low-dose bortezomib.
Because oxidative stress is a key element of endothelial dysfunction, we examined the vasoreactivity of isolated aortic rings. Unlike previously published data on coronary circulation, 23 endothelium-dependent vasorelaxation of aortic rings was not affected by PI in the present study. However, beneficial antioxidative effects of low-dose bortezomib treatment in LDR−/− mice did not translate into improved endothelium-dependent vasorelaxation. Taking recent studies into consideration, the effect of PI on endothelial function remains puzzling. 19 Recent reports suggested that chronic inhibition of the UPS mediates dysfunctional effects in coronary arteries of hypercholesterolemic pigs, 23 whereas vascular function in the renal circulation of the same model was shown to be improved. 24 Thus, in addition to possible inhibitor-specific and dose-dependent effects of PI on endothelial function, variable responses of different vascular beds to PI are conceivable. It is debatable whether data shown here are of minor relevance to vasomotor function of the thoracic aorta, which represents a conductance rather than a resistance vessel. Vasoreactivity of resistance vessels was not tested in the present study, but appears to be more suitable to illustrate the functional consequence of the endothelium-protective effects induced by low-dose bortezomib treatment in early atherosclerosis.
Antioxidative properties of low-dose PI have recently been shown to be the underlying mechanism for inhibition of tumor necrosis factor--induced monocyte adhesion to endothelial cells and attenuation of hypertension-induced VCAM-1 expression in hypertensive rats, representing an alternative anti-inflammatory pathway beyond inhibition of nuclear factor-kB translocation by PI. 11 The present study confirms anti-inflammatory effects in a widely accepted mouse model of atherosclerosis. We observed a PI-induced reduction of central proinflammatory mediators MCP-1 and VCAM-1. It appears that downregulation of MCP-1 and VCAM-1 is of functional relevance, because it leads to decreased subendothelial macrophage content in PI-treated hypercholesterolemic LDLR2/2 mice. Moreover, the WD-induced increase of IL-6 plasma levels was almost completely blocked by treatment with low-dose bortezomib. Because leukocytes are certainly the primary source of MCP-1 and IL-6 production, 25 anti-inflammatory capacities of low-dose PI are evidently not limited to resident vascular cells, but may also involve migrating inflammatory cells. Of note, attenuation of MCP-1 secretion was also observed in a previous in vitro study investigating the reduced secretion of MCP-1 and chemokine (C-C motif) ligand 5 in dendritic cells exposed to nontoxic doses of bortezomib. 26 Interestingly, another potentially protective effect by PI was demonstrated in a recent study: PI increased the expression of functional ATP-binding cassette transporters A1 and ATP-binding cassette transporters G1, thereby increasing the cholesterol efflux from macrophages and promoting overall reverse cholesterol transport in vivo. 27 Short-term treatment of BL6 with bortezomib resulted in enhancement of ATP-binding cassette transporters A1 and decrease of scavenger receptor class B, member 1, but was not accompanied by increase in high-density lipoprotein cholesterol. Chronic bortezomib treatment of hypercholesterinemic mice in our study did also not induce changes in high-density lipoprotein cholesterol and total cholesterol. However, we cannot exclude that beneficial effects on reverse cholesterol transport contribute to the antiatherogenic effect of bortezomib observed in our study.
Indeed, antioxidative and anti-inflammatory effects of low-dose bortezomib treatment resulted in significant reduction of early lesion size in hypercholesterolemic LDLR−/− mice, as shown by en face analysis of the aortic arch and by cross-sectional analysis of aortic root cryosections.
Earlier reports 23 suggest that chronic inhibition of the UPS aggravates atherosclerosis in coronary arteries of hypercholesterolemic pigs by causing oxidative stress, thereby promoting endothelial dysfunction and vascular inflammation This apparent contradiction to our results, which show beneficial actions of partial nonapoptotic PI in the vascular system, may be explained by considering dose-dependent and organ-specific effects of PI, as extensively discussed over the past 2 years. 5, 6, 28, 29 Although pronounced PI appears to stimulate reactive oxygen species production and proinflammatory processes in blood vessels, 23 inhibitor treatment at moderate doses provides antioxidative and thereby anti-inflammatory protection, as shown here in vivo and in earlier in vitro and in vivo models. 11
limitations
The present study provides the first in vivo demonstration of the beneficial action of low-dose PI on early lesion formation, which supports the concept of PI to counteract initiation of atherosclerosis. No conclusion can be drawn regarding the effect of PI in late-stage atherosclerosis. A recent study indicates that PI on developed lesions promotes features of a rupture-prone plaque phenotype in ApoE−/− mice without affecting the plaque size. 30 Because there is evidence for a dual role of the UPS in the course of atherogenesis, 5 a yet undefined timeframe for beneficial effects of PI may exist.
Currently, comparability to other studies is limited, because inhibitor concentrations vary among different studies. Future studies should take into account the pronounced dose dependency of PI-mediated effects as well as possible organ-specific effects to collectively explore the potential and the limitations of utilization of low-dose PI in atherosclerosis.
Investigation of the vasoreactivity of resistance arteries could clarify whether the currently described unchanged vasoreactivity in the thoracic aorta is modulated in smaller vessels.
Although there have been promising findings regarding atherosclerosis and prevention of restenosis, 31 therapeutic application of proteasome inhibitors in the cardiovascular system requires further profound and systematic investigations.
In conclusion, low-dose PI attenuates early atherosclerosis. These findings further highlight the involvement of the UPS in the pathophysiology of atherosclerosis. Specifically, the suspected role of the UPS in initiation of the disease by oxidative stress and inflammatory processes has been verified in vivo.
